Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Mainz Biomed BV

Healthcare US MYNZ

NoneUSD
0.00(0%)

Last update at 2026-04-16T21:05:10.219318Z

Day Range

--
LowHigh

52 Week Range

0.556.00
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap16.63M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-26.07467M
  • Revenue TTM0.90M
  • Revenue Per Share TTM0.06
  • Gross Profit TTM 0.18M
  • Diluted EPS TTM-2.15

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -26.38734M -11.69516M -0.58689M -0.95705M
Minority interest - - - -
Net income -26.45273M -12.07228M -0.88618M -1.17477M
Selling general administrative 17.83M 8.45M 0.35M 0.39M
Selling and marketing expenses 4.98M 0.96M 0.11M 0.18M
Gross profit 0.18M 0.18M 0.12M -0.06127M
Reconciled depreciation 0.38M 0.07M 0.06M 0.05M
Ebit -26.17475M -9.37926M -0.32581M -0.92191M
Ebitda -25.65282M -9.26632M -0.26535M -0.68267M
Depreciation and amortization 0.52M 0.11M 0.06M 0.24M
Non operating income net other - - - -
Operating income -26.17475M -9.37926M -0.32581M -0.92191M
Other operating expenses 26.70M 9.96M 0.85M 1.03M
Interest expense 0.29M 0.34M 0.27M 0.20M
Tax provision 0.00000M 0.00000M - 0.00000M
Interest income - - - -
Net interest income -0.28932M -0.33917M -0.26879M -0.20194M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.07M 0.38M 0.30M 0.22M
Total revenue 0.53M 0.58M 0.49M 0.28M
Total operating expenses 26.36M 9.56M 0.48M 0.69M
Cost of revenue 0.35M 0.40M 0.37M 0.34M
Total other income expense net -0.21258M -2.31590M -0.26108M -0.03515M
Discontinued operations - - - -
Net income from continuing ops -26.38734M -11.69516M -0.58689M -0.95705M
Net income applicable to common shares - -11.69010M -0.58689M -0.95705M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 15.41M 20.24M 10.04M 0.67M 0.72M
Intangible assets 3.39M - - - -
Earning assets - - - - -
Other current assets 0.94M 801.96M 863.91M 0.02M 0.02M
Total liab 12.16M 6.14M 3.68M 3.41M 2.67M
Total stockholder equity 3.25M 14.10M 6.36M -2.74155M -1.95030M
Deferred long term liab - - - - -
Other current liab 1.51M 1.58M 0.27M 0.19M 0.05M
Common stock 0.24M 0.16M 0.14M 0.11M 0.11M
Capital stock 0.24M 0.16M 0.14M 0.11M 0.11M
Retained earnings -69.32802M -43.03229M -16.64496M -4.95486M -4.36796M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 7.07M 17.14M 8.73M 0.12M 0.20M
Cash and equivalents - - - - -
Total current liabilities 9.24M 4.24M 1.35M 0.70M 0.46M
Current deferred revenue 0.14M - - 0.00151M 0.00250M
Net debt 0.35M -13.91352M -6.15115M 2.86M 2.21M
Short term debt 5.22M 1.33M 0.25M 0.27M 0.21M
Short long term debt 4.94M 1.04M 0.19M 0.22M 0.17M
Short long term debt total 7.42M 3.23M 2.58M 2.98M 2.41M
Other stockholder equity 51.51M 38.83M 13.13M 2.11M -
Property plant equipment - - 0.43M 0.49M -
Total current assets 8.98M 18.38M 9.61M 0.19M 0.26M
Long term investments - - - - -
Net tangible assets - - 6.36M -2.74155M -
Short term investments - - - - -
Net receivables 0.35M 0.26M 0.11M 0.04M 0.04M
Long term debt 1.03M 0.94M 1.94M 0.45M 0.37M
Inventory 0.61M 0.18M -863.14017M - -
Accounts payable 2.36M 1.33M 0.83M 0.25M 0.20M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 20.83M 18.13M 9.74M 2.11M 2.31M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00011M 0.02M - - -
Deferred long term asset charges - - - - -
Non current assets total 6.43M 1.86M 0.43M 0.49M 0.46M
Capital lease obligations 1.45M 1.24M 0.44M 0.50M 0.45M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.65848M 1.20M -0.00968M 0.00000M
Change to liabilities 0.00000M 0.67M 0.16M 0.08M
Total cashflows from investing activities - 1.20M -0.00968M -0.00968M
Net borrowings - 0.19M 0.40M 0.42M
Total cash from financing activities 23.94M 10.61M 0.40M 0.42M
Change to operating activities - -0.83356M -0.00251M 0.00011M
Net income -26.38734M -11.69010M -0.58689M -0.95705M
Change in cash 8.41M 8.60M -0.08102M -0.02594M
Begin period cash flow 8.73M 0.12M 0.20M 0.23M
End period cash flow 17.14M 8.73M 0.12M 0.20M
Total cash from operating activities -14.76959M -3.22032M -0.46874M -0.41650M
Issuance of capital stock 23.87M 10.43M - 0.00000M
Depreciation 0.38M 0.07M 0.06M 0.05M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory -0.17238M -670.72500M - -
Change to account receivables - 0.02M -0.09915M 0.34M
Sale purchase of stock - - - -
Other cashflows from financing activities 0.38M 0.25M 0.44M 0.45M
Change to netincome 9.85M 8.40M -0.09227M 0.02M
Capital expenditures 0.66M 0.02M 0.00968M 0.00968M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 1.39M -0.13862M 0.06M 0.42M
Stock based compensation 9.82M 6.43M - 0.00000M
Other non cash items 0.03M 2.11M 0.00011M 0.06M
Free cash flow -15.42807M -3.23703M -0.47842M -0.41650M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MYNZ
Mainz Biomed BV		 - -% - - - 23.71 6.53 24.69 -0.7948
TMO
Thermo Fisher Scientific Inc		 2.92 0.63% 464.61 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -0.59 0.33% 177.17 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 2.73 2.20% 127.06 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 16.00 2.93% 562.09 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

Mainz Biomed BV

Robert Koch Strasse 50, Mainz, Germany, 55129

Key Executives

Name Title Year Born
Mr. Guido Baechler CEO & Director 1965
Mr. William J. Caragol Chief Financial Officer 1967
Mr. Philipp Freese Chief Operating Officer 1983
Dr. Moritz Eidens Ph.D. Chief Science Officer & Director 1984
Mr. Darin S. Leigh Chief Commercial Officer NA
Mr. Guido Baechler CEO & Executive Director 1965
Dr. Christopher Von Torne P.M.P., Ph.D. Chief Operating Officer 1972
Dr. Frank Krieg-Schneider Chief Technology Officer 1962
Dr. Moritz Eidens Ph.D. Chief Science Officer & Executive Director 1984
Stefan Erlach Head of Human Resources NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.